Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
10+ emerging markets, Japan & ANZ transition in final phase
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
